The therapy with ATRA and ATO is not effective on ZBTB16-RARA AML, and the resistance to ATO is due to the lack of an ATO-binding site, whereas although ATRA induces the degradation of the fusion protein, differentiation and apoptosis do not occur, and there is no clinical response. Here, ZBTB16 is linked to acute myeloid leukemia.